Why the study?
There is no consensus regarding the outcome-oriented therapeutic management of vasoplegic syndrome after cardiac surgery.
What is the efficacy and safety of various vasopressors and adjuvant therapies for managing vasoplegic syndrome after cardiovascular surgery?
What is the efficacy and safety of various vasopressors and adjuvant therapies for managing vasoplegic syndrome after cardiovascular surgery?
Multidrug therapy targeting multiple receptor systems, including catecholamine-sparing agents and adjuvants, is recommended for managing refractory vasoplegic syndrome after cardiac surgery.
Answers are grounded in this paper and cite their sources.
Multidrug regimens should be prioritized for refractory VPS post-cardiac surgery; extends evidence supporting multimodal vasopressor strategies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Datt et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: